Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: time to reflect again?

Editorial

John M S Bartlett et al. J Clin Oncol. 2011.

. 2011 Nov 10;29(32):4219-21.

doi: 10.1200/JCO.2011.37.5824. Epub 2011 Oct 11.

No abstract available

Comment in

Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Bhargava R, Dabbs DJ. Bhargava R, et al. J Clin Oncol. 2012 Feb 10;30(5):570-1. doi: 10.1200/JCO.2011.40.1323. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231038 No abstract available.

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R. Dabbs DJ, et al. J Clin Oncol. 2011 Nov 10;29(32):4279-85. doi: 10.1200/JCO.2011.34.7963. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990395
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Cuzick J, et al. J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990413